Table 3. Multivariate Cox proportional hazards regression models predicting duration of longest PFS.
| Clinical Feature | mtp53 | wtp53 | ||||
|---|---|---|---|---|---|---|
| Hazard Ratio | 95% CI | P-value | Hazard Ratio | 95% CI | P-value | |
| Age* | 0.96 | 0.94-0.99 | 0.010 | 0.99 | 0.97-1.02 | 0.651 |
| Race (Non-Caucasian vs. Caucasian) | 0.74 | 0.34-1.62 | 0.456 | 1.54 | 0.84-2.82 | 0.167 |
| Tumor histology group§(Recommended vs. not recommended) | 0.56 | 0.29-1.09 | 0.086 | 0.84 | 0.38-1.84 | 0.657 |
| Bevacizumab-containing regimen (Yes vs. no) | 0.21 | 0.09-0.454 | <0.0001 | 1.82 | 0.661-5.02 | 0.247 |
*
Age as continuous variable, § Recommended versus not recommended means dichotomized into tumor histologies for which bevacizumab is or is not FDA-approved